Phase 1 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are considered high risk for developing pancreatic cancer (falling into one of three groups below) and are already taking part in a pancreatic monitoring programme, AND who have an abnormality found on a pancreas scan (such as a pancreatic cyst).

• High Risk Group 1 (family history): People aged 55 or older (or at least 10 years younger than the youngest family member who had pancreatic cancer), who come from a family where 2 or more members have had pancreatic cancer, and where at least one of those relatives is a close (first-degree) family member such as a parent, sibling, or child.

• High Risk Group 2 (certain gene mutations — higher risk): People aged 40 or older who carry the FAMMM (p16/CDKN2A) gene mutation, regardless of family history; OR people aged 50 or older (or 10 years younger than the youngest affected relative) who carry a BRCA2, ATM, or PALB2 gene mutation. Proof of mutation from an approved certified laboratory is required.

• High Risk Group 3 (certain gene mutations — moderate risk): People aged 50 or older (or 10 years younger than the youngest affected relative) who carry a BRCA1 or Lynch syndrome (HNPCC)-related gene mutation, and who have more than one family member with pancreatic cancer, at least one of whom is a close (first- or second-degree) relative. Proof of mutation from an approved certified laboratory is required.

• Cohort A participants: People already being monitored with pancreas scans (such as MRI, CT, or endoscopic ultrasound) for an abnormality such as a pancreatic cyst or other early tissue changes.

• Cohort B participants: People with a pancreatic cyst that has features considered concerning enough by their surgeon to recommend surgical removal, and whose cyst fluid testing shows one of six specific KRAS gene mutations included in this study.

• People whose organ and blood test results meet the health standards set out by the study.

• People who are willing and able to sign a consent form confirming they understand the study.

• Women who could become pregnant must have a negative pregnancy test and must follow the contraception guidelines set out in the study protocol.

• Men must use an acceptable form of contraception during the study.

Who may not be able to join:

• People who are expected to need other cancer treatments (systemic or localised) during the study period.

• People who have used corticosteroids or immune-suppressing medications within 4 weeks before the first study treatment.

• People who have received any experimental medical device, a live vaccine, allergen desensitisation therapy, or had major surgery within 4 weeks before the first study treatment.

• People who have HIV, hepatitis B, or hepatitis C infection.

• People with serious ongoing health conditions that are not well controlled, including serious infections, heart failure, unstable heart conditions, irregular heart rhythms, cancer that has spread to other parts of the body, or mental health or social circumstances that would make it difficult to follow the study schedule.

• People who have been diagnosed with an immune system deficiency condition.

• People who, in the opinion of the study doctor, have any other medical, psychological, or social reason that makes participation unsuitable (confirm with trial site).

• People who are unwilling or unable to follow the study schedule.

• People who are pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.